Efferon LPS Hemoadsorption in in Patients With Thermal Burns
Extracorporeal Blood Purification Using Efferon LPS Hemoadsorption in Patients With Thermal Burns: Pilot Study
The aim of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoadsorption using the Efferon® LPS device to reduce the severity of clinical symptoms and to prevent the progression of multiple organ dysfunction or to arrest its development in patients with burn disease with an RFI score ≥71 and ≤181.
Patients will be randomized in two groups: control group receiving baseline therapy (including CRRT) and treatment group receiving baseline therapy and Efferon® LPS hemoadsorption in combination with CRRT.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Extensive burns are a severe form of trauma that, according to the World Health Organization, cause more than 180,000 deaths worldwide each year. Burn injury is not only a local tissue injury at the site of the damaging agent, but also triggers a complex systemic response to trauma. Severe burn injury induces a systemic inflammatory response associated with generalized microcirculatory disturbances in organs and tissues, cellular dystrophy and destruction, and the development of multiple organ dysfunction and failure. Burn trauma causes massive release of damage-associated molecular patterns (DAMPs) and pro-inflammatory cytokines, leading to systemic inflammatory response syndrome (SIRS), which may result in multiple organ failure and death. Mortality associated with multiple organ failure in burn patients reaches 81-87% among patients who develop this condition, and multiple organ failure remains the leading cause of death in burn patients. Among patients with a Sequential Organ Failure Assessment (SOFA) score ≥4 within the first 24 hours after injury, mortality reaches 81%.
The Efferon LPS hemoadsorption device was developed for use in sepsis, leveraging its ability to effectively target both primary and secondary inflammatory mediators. However, this approach also has significant potential in the treatment of burn injury, a condition characterized by a complex inflammatory response.
The goal of this study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoadsorption using the Efferon LPS device to reduce the severity of clinical manifestations and to prevent progression of multiple organ dysfunction, or mitigate it if already developed, in patients with burn disease and an RFI score ≥71 and ≤181.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Alexandr Shelehov-Kravchenko, PhD, MD
- Telefoonnummer: +79636564765
- E-mail: ais@efferon.ru
Studie Locaties
-
-
-
Moscow, Rusland, 129090
- N.V. Sklifosovsky Research Institute for Emergency Medicine
-
Contact:
- Vladimir Kulabukhov, PhD, MD
- Telefoonnummer: +79255068081
- E-mail: v.kulabukhov@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Thermal burns (flame, scald, or contact burns), including cases combined with inhalation injury
- Revised Frank Index (RFI) score ≥71 and ≤181
- Indication for extracorporeal therapy within the first 10 days after injury
- The patient's condition allows Efferon LPS therapy to be performed for at least 6 hours
Exclusion Criteria:
- Isolated thermal-inhalation injury
- Chemical, electrical, or solar burns of the skin
- Combined skin burns with frostbite and/or general hypothermia
- Combined trauma (electrical injury; traumatic brain injury other than concussion or mild cerebral contusion; skull, spinal, thoracic, pelvic, or femoral fractures) or acute pre-existing pathology prior to hospital admission (acute myocardial infarction, stroke, community-acquired pneumonia, or acute surgical conditions) that may influence the course and outcome of burn disease
- Cardiopulmonary resuscitation at the pre-hospital stage
- End-stage renal disease
- Acute pulmonary embolism confirmed by imaging
- Emergency surgical treatment
- Any other condition which, in the investigator's opinion, precludes inclusion of the patient in the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Baseline therapy
Patients receiving standard treatment for the treatment of thermal burns without the use of hemoadsorption methods, but who are prescribed continuous renal replacement therapy (CRRT) for renal and non-renal indications.
|
|
|
Experimenteel: Baseline therapy + Efferon LPS
Patients receiving standard therapy for the treatment of thermal burns, along with Efferon LPS hemoadsorption procedures in combination with continuous renal replacement therapy (CRRT).
|
Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.hemoadsorption
procedures, each lasting 6-12 hours, with an interval of at least 24 hours between hemoadsorption sessions (from the start of the first procedure).
The procedures are performed in combination with continuous renal replacement therapy (CRRT).
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Need for vasopressor support
Tijdsspanne: 1-28 days
|
Need for vasopressors according to the Vasoactive inotropic score (VIS 2020) heart rate scale.
VIS is calculated as a weighted sum of all administered vasoactive inotropic agents.
|
1-28 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Horowitz oxygenation index
Tijdsspanne: 1-28 days
|
Value of oxygenation index (Pa02 / Fi02 (Pa).
|
1-28 days
|
|
Renal replacement therapy (RRT) free days
Tijdsspanne: 1-28 days
|
RRT-free days = 0 if the subject dies within 28 days of starting renal replacement therapy. RRT-free days = 28 - x if RRT is successfully discontinued x days after initiation. RRT-free days = 0 if the subject requires RRT for more than 28 days. |
1-28 days
|
|
28 and 60 days mortality
Tijdsspanne: 1-60 days
|
Mortality rate
|
1-60 days
|
|
Length of stay in the intensive care unit
Tijdsspanne: 1-60 days
|
Time (number of days) from study enrollment to transfer from the intensive care unit within 60 days
|
1-60 days
|
|
Duration of hospitalization
Tijdsspanne: 1-60 days
|
Time (number of days) from study enrollment to discharge from the hospital
|
1-60 days
|
|
Frequency of septic complications
Tijdsspanne: 1-28 days
|
Percentage of patients with septic complications
|
1-28 days
|
|
Frequency of surgical interventions
Tijdsspanne: 1-28 days
|
Percentage of patients requiring surgery
|
1-28 days
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Vladimir Kulabukhov, PhD, MD, N.V. Sklifosovsky Research Institute for Emergency Medicine
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- efferon-lps-2026-01
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .